Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, clopidogrel (Plavix®) cannot be endorsed for use within NHS Wales in combination with aspirin for the prevention of atherothrombotic and thromboembolic events in adult patients with atrial fibrillation. |
||
|
||
Medicine details |
||
| Medicine name | clopidogrel (Plavix®) | |
| Formulation | film-coated tablet | |
| Reference number | 435 | |
| Indication | In combination with aspirin for the prevention of atherothrombotic and thromboembolic events in adult patients with atrial fibrillation |
|
| Company | Sanofi-Aventis Ltd/Bristol-Myers Squibb Pharmaceuticals Ltd | |
| BNF chapter | Cardiovascular system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 01/09/2011 | |